Calcitriol

The active form of vitamin D, used for calcium and bone problems in chronic kidney disease and for low calcium from hypoparathyroidism.

psilodex.org/m/calcitriol · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: 5–8 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Calcitriol”, v2026.10.05. psilodex.org/m/calcitriol

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Secondary hyperparathyroidism and bone disease in moderate to severe chronic kidney disease not yet on dialysis
Low blood calcium and bone disease in people on chronic dialysis
Low blood calcium from hypoparathyroidism

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; no linking mechanism is described. Separately, this active vitamin D can raise blood calcium too high in excess.

Detail Not studied with psilocybin, and no mechanism linking them has been described. Separately, calcitriol is the most active form of vitamin D; its label warns that too much can cause high blood calcium, which can become severe. Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: 5–8 h (FDA label, checked 2026-10-04) After single oral doses in healthy adults.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Dehydration or electrolyte risk: Can cause dehydration or shifts in sodium or potassium. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Chronic kidney disease (indication; severe chronic illness)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

ROCALTROL (calcitriol) capsules and oral solution (Validus) · FDA label (DailyMed) — Dehydration or electrolyte risk: Warnings "Progressive hypercalcemia due to overdosage of vitamin D and its metabolites may be so severe as to require emergency attention." | "Rocaltrol is the most potent metabolite of vitamin D available." | "The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects."
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →